Please note, this OEL/ADE monograph also applies to diflunisal meglumine (CAS RN Not Applicable) and diflunisal phosphate (CAS RN 84958-45-2). Diflunisal oral therapy is indicated for osteoarthritis, pain and rheumatoid arthritis. Diflunisal is a nonsteroidal anti-inflammatory drug with analgesic, anti-inflammatory and antipyretic property. It is a peripherally-acting non-narcotic analgesic that inhibits prostaglandin synthetase resulting in decreased prostaglandin, which is a known mediator of pain and inflammation.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Diflunisal, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.